Drugs / LT-02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02849951 | Jul 2016 → Mar 2019 | ulcerative colitis | Prometheus Laboratories | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LT-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02849951 ↗ |
| Known as | Phosphatidylcholine | “The purpose of this study is to determine whether Phosphatidylcholine (LT-02) add on treatment is effective and safe for the induction of remission in ulcerative colitis...” NCT02849951 ↗ |
| Route | Oral | “administered orally via 1.6 g BID for up to 12 weeks” NCT02849951 ↗ |